26. Referanser

Al Natour, R. H., Saund, M. S., Sanchez, V. M., Whang, E. E., Sharma, A. M., Huang, Q., Boosalis, V. A., & Gold, J. S. (2012). Tumor size and depth predict rate of lymph node metastasis in colon carcinoids and can be used to select patients for endoscopic resection. Journal of Gastrointestinal Surgery, 16(3), 595-602.

Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., ... Winchester, D. P. (2017). The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA: A Cancer Journal for Clinicians, 67(2), 93-99.

Ammann, M., Gudmundsdottir, H., Antwi, S. K. A., Santol, J., Podrascanin, V., Thiels, C. A., Warner, S. G., Truty, M. J., ... Starlinger, P. P. (2025). Long-term outcome of cytoreductive hepatectomy in metastatic neuroendocrine neoplasia G3: A single center retrospective analysis. European Journal of Surgical Oncology, 51(8), 109678.

Amstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. H. M., Swen, J. J., Klein, T. E., McLeod, H. L., ... Schwab, M. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clinical Pharmacology and Therapeutics, 103(2), 210-216.

Apostolidis, L., Dal Buono, A., Merola, E., Jann, H., Jäger, D., Wiedenmann, B., Winkler, E. C., & Pavel, M. (2021). Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3). Cancers, 13(8)

Baechle, J. J., Marincola Smith, P., Tan, M., Solórzano, C. C., Lopez-Aguiar, A. G., Dillhoff, M., Beal, E. W., Poultsides, G., ... Idrees, K. (2020). Specific Growth Rate as a Predictor of Survival in Pancreatic Neuroendocrine Tumors: A Multi-institutional Study from the United States Neuroendocrine Study Group. Annals of Surgical Oncology, Apr 23 [Epub ahead of print]

Bergsland, E. K., & Nakakura, E. K. (2014). Neuroendocrine tumors of unknown primary: is the primary site really not known?. JAMA surgery, 149(9), 889-90.

Bernard, V., Lombard-Bohas, C., Taquet, M. C., Caroli-Bosc, F. X., Ruszniewski, P., Niccoli, P., Guimbaud, R., Chougnet, C. N., ... Tumors, F. G. E. (2013). Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. European Journal of Endocrinology, 168(5), 665-674.

Bertani, E., Fazio, N., Radice, D., Zardini, C., Spinoglio, G., Chiappa, A., Ribero, D., Biffi, R., ... Falconi, M. (2017). Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation. European Journal of Surgical Oncology, 43(2), 372-379.

Bhattacharyya, S., Toumpanakis, C., Caplin, M. E., & Davar, J. (2008). Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. American Journal of Cardiology, 102(7), 938-42.

Binderup, T., Knigge, U., Loft, A., Mortensen, J., Pfeifer, A., Federspiel, B., Hansen, C. P., Hojgaard, L., & Kjaer, A. (2010). Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. Journal of nuclear medicine, 51(5), 704-12.

Bodei, L., Kidd, M., Paganelli, G., Grana, C. M., Drozdov, I., Cremonesi, M., Lepensky, C., Kwekkeboom, D. J., ... Modlin, I. M. (2015). Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. European Journal of Nuclear Medicine and Molecular Imaging, 42(1), 5-19.

Boss, M., Eriksson, O., Mikkola, K., Eek, A., Brom, M., Buitinga, M., Brouwers, A. H., Velikyan, I., ... Gotthardt, M. (2024). Improved Localization of Insulinomas Using (68)Ga-NODAGA-Exendin-4 PET/CT. Journal of nuclear medicine, 65(12), 1959-1964.

Boss, M., Rottenburger, C., Brenner, W., Blankenstein, O., Prasad, V., Prasad, S., Coppi, P., Kühnen, P., ... Gotthardt, M. (2022). (68)Ga-NODAGA-Exendin-4 PET/CT Improves the Detection of Focal Congenital Hyperinsulinism. Journal of nuclear medicine, 63(2), 310-315.

Boyar Cetinkaya, R., Aagnes, B., Myklebust, T., & Thiis-Evensen, E. (2018). Survival in neuroendocrine neoplasms; A report from a large Norwegian population-based study. International Journal of Cancer, 142(6), 1139-1147.

Boyar Cetinkaya, R., Aagnes, B., Thiis-Evensen, E., Tretli, S., Bergestuen, D. S., & Hansen, S. (2017). Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010. Neuroendocrinology, 104(1), 1-10.

Brabander, T., van der Zwan, W. A., Teunissen, J. J. M., Kam, B. L. R., Feelders, R. A., de Herder, W. W., van Eijck, C. H. J., Franssen, G. J. H., ... Kwekkeboom, D. J. (2017). Long-Term Efficacy, Survival, and Safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clinical Cancer Research, 23(16), 4617-4624.

Brierley, J., Gospodarowicz, M., Wittekind, C. (2016). TNM Classification of Malignant Tumours. Wiley-Blackwell.

Bussolati, G., Volante, M., & Papotti, M. (2001). Classic and recent special stains used in differential diagnosis of endocrine tumors. Endocrine Pathology, 12(4), 379-87.

Caplin, M. E., Pavel, M., Cwikla, J. B., Phan, A. T., Raderer, M., Sedlackova, E., Cadiot, G., Wolin, E. M., ... Investigators, C. (2014). Lanreotide in metastatic enteropancreatic neuroendocrine tumors. New England Journal of Medicine, 371(3), 224-33.

Capurso, G., Bettini, R., Rinzivillo, M., Boninsegna, L., Delle Fave, G., & Falconi, M. (2011). Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review. Neuroendocrinology, 93(4), 223-9.

Carlsen, E. A., Fazio, N., Granberg, D., Grozinsky-Glasberg, S., Ahmadzadehfar, H., Grana, C. M., Zandee, W. T., Cwikla, J., ... Sorbye, H. (2019). Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocrine-Related Cancer, 26(2), 227-239.

Chan, J. A., Geyer, S., Zemla, T., Knopp, M. V., Behr, S., Pulsipher, S., Ou, F. S., Dueck, A. C., ... Meyerhardt, J. A. (2025). Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. New England Journal of Medicine, 392(7), 653-665.

Condron, M. E., Pommier, S. J., & Pommier, R. F. (2016). Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis. Surgery, 159(1), 358-67.

Connolly, H. M., Nishimura, R. A., Smith, H. C., Pellikka, P. A., Mullany, C. J., & Kvols, L. K. (1995). Outcome of cardiac surgery for carcinoid heart disease. Journal of the American College of Cardiology, 25(2), 410-6.

Cordero-Hernandez, I. S., Ross, A. C., Dasari, A., Halperin, D. M., Chasen, B., & Yao, J. C. (2024). Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy. Endocrine-Related Cancer, 31(4)

Crinò, S. F., Ammendola, S., Meneghetti, A., Bernardoni, L., Conti Bellocchi, M. C., Gabbrielli, A., Landoni, L., Paiella, S., ... Manfrin, E. (2021). Comparison between EUS-guided fine-needle aspiration cytology and EUS-guided fine-needle biopsy histology for the evaluation of pancreatic neuroendocrine tumors. Pancreatology, 21(2), 443-450.

Dam, G., Grønbæk, H., Sorbye, H., Thiis Evensen, E., Paulsson, B., Sundin, A., Jensen, C., Ebbesen, D., ... Tiensuu Janson, E. (2020). Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors. Neuroendocrinology, 110(3-4), 217-224.

Dasari, A., Mehta, K., Byers, L. A., Sorbye, H., & Yao, J. C. (2018). Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer, 124(4), 807-815.

Daskalakis, K., Karakatsanis, A., Hessman, O., Stuart, H. C., Welin, S., Tiensuu Janson, E., Öberg, K., Hellman, P., ... Stålberg, P. (2018). Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival. JAMA oncology, 4(2), 183-189.

Davar, J., Connolly, H. M., Caplin, M. E., Pavel, M., Zacks, J., Bhattacharyya, S., Cuthbertson, D. J., Dobson, R., ... Toumpanakis, C. (2017). Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors: An Expert Statement. Journal of the American College of Cardiology, 69(10), 1288-1304.

de Mestier, L., Lamarca, A., Hernando, J., Zandee, W., Alonso-Gordoa, T., Perrier, M., Walenkamp, A. M., Chakrabarty, B., ... Cros, J. (2021). Treatment outcomes of advanced digestive well-differentiated grade 3 NETs. Endocrine-Related Cancer, 28(8), 549-561.

de Mestier, L. A., Apostolidis, L. B., Koumarianou, A. C., Hernando Cubero, J. D., Riechelmann, R. E., Bergsland, E. F., Cingarlini, S. G., Shaheen, S. H., ... Strosberg, J. L. (2025). Efficacy of immune checkpoint inhibitors (ICI) in patients with advanced pancreatic NETs displaying high TMB and MMR alterations following treatment with alkylating agents. Journal of Neuroendocrinology, 37(S1), 174.

Del Prete, M., Fiore, F., Modica, R., Marotta, V., Marciello, F., Ramundo, V., Di Sarno, A., Carratu, A., ... Multidisciplinary Group for NeuroEndocrine Tumors of, N. (2014). Hepatic arterial embolization in patients with neuroendocrine tumors. Journal of experimental & clinical cancer research : CR, 33, 43.

Delle Fave, G., O'Toole, D., Sundin, A., Taal, B., Ferolla, P., Ramage, J. K., Ferone, D., Ito, T., ... Vienna Consensus Conference, p. (2016). ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology, 103(2), 119-24.

Delpassand, E. S., Yazdi, S. M., Ghantoji, S., Nakasato, A., Strickland, C., Nunez, R., Shafie, A., Cork, S., ... Patel, J. (2024). Effectiveness and Safety of Retreatment with (177)Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States. Journal of nuclear medicine, 65(5), 746-752.

Deng, H. Y., Ni, P. Z., Wang, Y. C., Wang, W. P., & Chen, L. Q. (2016). Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection. Journal of Thoracic Disease, 8(6), 1250-6.

Dhar, J., Samanta, J., Nabi, Z., Aggarwal, M., Facciorusso, A., Conti Bellocchi, M. C., & Crinò, S. F. (2024). Endoscopic ultrasound-guided radiofrequency ablation of pancreatic insulinoma: a state of the art review. Expert Review of Gastroenterology & Hepatology, 18(1-3), 37-53.

Donadio, M. D., Brito Â, B., & Riechelmann, R. P. (2023). A systematic review of therapeutic strategies in gastroenteropancreatic grade 3 neuroendocrine tumors. Therapeutic Advances in Medical Oncology, 15, 1.7588359231156218E16.

Duan, K., & Mete, O. (2016). Algorithmic approach to neuroendocrine tumors in targeted biopsies: Practical applications of immunohistochemical markers. Cancer Cytopathology, 124(12), 871-884.

Eads, J. R., Halfdanarson, T. R., Asmis, T., Bellizzi, A. M., Bergsland, E. K., Dasari, A., El-Haddad, G., Frumovitz, M., ... Chan, J. A. (2023). Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Endocrine-Related Cancer, 30(8)

Elvebakken, H., Hjortland, G. O., Garresori, H., Andresen, P. A., Janssen, E. A. M., Vintermyr, O. K., Lothe, I. M. B., & Sorbye, H. (2023). Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms. Journal of Neuroendocrinology, 35(4), e13256.

Eriksson, B., & Oberg, K. (1993). An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncologica, 32(2), 203-8.

Exarchou, K., Kamieniarz, L., Tsoli, M., Victor, A., Oleinikov, K., Khan, M. S., Srirajaskanthan, R., Mandair, D., ... Toumpanakis, C. (2021). Is local excision sufficient in selected grade 1 or 2 type III gastric neuroendocrine neoplasms?. Endocrine, 74(2), 421-429.

Fendrich, V., Langer, P., Waldmann, J., Bartsch, D. K., & Rothmund, M. (2007). Management of sporadic and multiple endocrine neoplasia type 1 gastrinomas. British Journal of Surgery, 94(11), 1331-41.

Fiore, F., Del Prete, M., Franco, R., Marotta, V., Ramundo, V., Marciello, F., Di Sarno, A., Carratu, A. C., ... Faggiano, A. (2014). Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine, 47(1), 177-82.

Fischer, L., Bergmann, F., Schimmack, S., Hinz, U., Priess, S., Muller-Stich, B. P., Werner, J., Hackert, T., & Buchler, M. W. (2014). Outcome of surgery for pancreatic neuroendocrine neoplasms. British Journal of Surgery, 101(11), 1405-12.

Fykse, V., Sandvik, A. K., & Waldum, H. L. (2005). One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release. Scandinavian Journal of Gastroenterology, 40(11), 1269-74.

Ganeshan, D., Bhosale, P., Yang, T., & Kundra, V. (2013). Imaging features of carcinoid tumors of the gastrointestinal tract. AJR. American journal of roentgenology, 201(4), 773-86.

Gedde-Dahl, M., Thiis-Evensen, E., Tjolsen, A. M., Mordal, K. S., Vatn, M., & Bergestuen, D. S. (2013). Comparison of 24-h and overnight samples of urinary 5-hydroxyindoleacetic acid in patients with intestinal neuroendocrine tumors. Endocrine connections, 2(1), 50-4.

Gincul, R., Ponchon, T., Napoleon, B., Scoazec, J. Y., Guillaud, O., Saurin, J. C., Ciocirlan, M., Lepilliez, V., ... Walter, T. (2016). Endoscopic treatment of sporadic small duodenal and ampullary neuroendocrine tumors. Endoscopy, 48(11), 979-986.

Girard, N., Mazieres, J., Otto, J., Lena, H., Lepage, C., Egenod, T., Smith, D., Madelaine, J., ... Walter, T. (2021). LBA41 Nivolumab (nivo) +/- ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC). Annals of Oncology, 32(Supplement 5), S1318.

Hallet, J., Law, C. H., Cukier, M., Saskin, R., Liu, N., & Singh, S. (2015). Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer, 121(4), 589-97.

Hashim, Y. M., Trinkaus, K. M., Linehan, D. C., Strasberg, S. S., Fields, R. C., Cao, D., & Hawkins, W. G. (2014). Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Annals of Surgery, 259(2), 197-203.

Heetfeld, M., Chougnet, C. N., Olsen, I. H., Rinke, A., Borbath, I., Crespo, G., Barriuso, J., Pavel, M., ... other Knowledge Network, m. (2015). Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocrine-Related Cancer, 22(4), 657-64.

Hentic, O., Hammel, P., Couvelard, A., Rebours, V., Zappa, M., Palazzo, M., Maire, F., Goujon, G., ... Ruszniewski, P. (2012). FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocrine-Related Cancer, 19(6), 751-7.

Hughes, M. S., Azoury, S. C., Assadipour, Y., Straughan, D. M., Trivedi, A. N., Lim, R. M., Joy, G., Voellinger, M. T., ... Wank, S. A. (2016). Prospective evaluation and treatment of familial carcinoid small intestine neuroendocrine tumors (SI-NETs). Surgery, 159(1), 350-6.

Iacovelli, R., Palazzo, A., Mezi, S., Morano, F., Naso, G., & Cortesi, E. (2012). Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncologica, 51(7), 873-9.

Janson, E. T., Holmberg, L., Stridsberg, M., Eriksson, B., Theodorsson, E., Wilander, E., & Oberg, K. (1997). Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Annals of Oncology, 8(7), 685-90.

Jensen, K. H., Hilsted, L., Jensen, C., Mynster, T., Rehfeld, J. F., & Knigge, U. (2013). Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors. Scandinavian Journal of Gastroenterology, 48(1), 70-7.

Jensen, R. T., Cadiot, G., Brandi, M. L., de Herder, W. W., Kaltsas, G., Komminoth, P., Scoazec, J. Y., Salazar, R., ... Barcelona Consensus Conference, p. (2012). ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology, 95(2), 98-119.

Jesinghaus, M., Konukiewitz, B., Keller, G., Kloor, M., Steiger, K., Reiche, M., Penzel, R., Endris, V., ... Klöppel, G. (2017). Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas. Modern Pathology, 30(4), 610-619.

Jiao, Y., Shi, C., Edil, B. H., de Wilde, R. F., Klimstra, D. S., Maitra, A., Schulick, R. D., Tang, L. H., ... Papadopoulos, N. (2011). DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science, 331(6021), 1199-203.

Joseph, N. M., Umetsu, S. E., Kim, G. E., Terry, M., Perry, A., Bergsland, E., & Kakar, S. (2024). Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53. Endocrine Pathology, 35(4), 325-337.

Kaasa, S., Loge, J. H. (2016). Palliasjon: nordisk lærebok. Gyldendal.

Kaçmaz, E., Heidsma, C. M., Besselink, M. G. H., Dreijerink, K. M. A., Klümpen, H. J., Nieveen van Dijkum, E. J. M., & Engelsman, A. F. (2019). Treatment of Liver Metastases from Midgut Neuroendocrine Tumours: A Systematic Review and Meta-Analysis. Journal of clinical medicine, 8(3)

Kanakis, G., & Kaltsas, G. (2012). Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best practice & research. Clinical gastroenterology, 26(6), 791-802.

Kasajima, A., Pfarr, N., Mayr, E. M., Ura, A., Moser, E., von Werder, A., Agaimy, A., Pavel, M., & Klöppel, G. (2024). Rapid Evolution of Metastases in Patients with Treated G3 Neuroendocrine Tumors Associated with NEC-Like Transformation and TP53 Mutation. Endocrine Pathology, 35(4), 313-324.

Konukiewitz, B., Schlitter, A. M., Jesinghaus, M., Pfister, D., Steiger, K., Segler, A., Agaimy, A., Sipos, B., ... Klöppel, G. (2017). Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20. Modern Pathology, 30(4), 587-598.

Korse, C. M., Taal, B. G., van Velthuysen, M. L., & Visser, O. (2013). Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. European Journal of Cancer, 49(8), 1975-83.

Kos-Kudła, B., Castaño, J. P., Denecke, T., Grande, E., Kjaer, A., Koumarianou, A., de Mestier, L., Partelli, S., ... Fazio, N. (2023). European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. Journal of Neuroendocrinology, 35(12), e13343.

Ku, G. Y., Minsky, B. D., Rusch, V. W., Bains, M., Kelsen, D. P., & Ilson, D. H. (2008). Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience. Annals of Oncology, 19(3), 533-7.

Kukar, M., Groman, A., Malhotra, U., Warren, G. W., Bogner, P., Nwogu, C. E., Demmy, T. L., & Yendamuri, S. (2013). Small cell carcinoma of the esophagus: a SEER database analysis. Annals of Surgical Oncology, 20(13), 4239-44.

Kunz, P. L., Catalano, P. J., Nimeiri, H., Fisher, G. A., Longacre, T. A., Suarez, C. J., Yao, J. C., Kulke, M. H., ... Benson, A. B. (2018). A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). Journal of Clinical Oncology, 36(15_suppl), 4004.

Lamberti, G., Panzuto, F., Pavel, M., O'Toole, D., Ambrosini, V., Falconi, M., Garcia-Carbonero, R., Riechelmann, R. P., ... Campana, D. (2024). Gastric neuroendocrine neoplasms. Nature reviews. Disease primers, 10(1), 25.

Lepage, C., Bouvier, A. M., & Faivre, J. (2013). Endocrine tumours: epidemiology of malignant digestive neuroendocrine tumours. European Journal of Endocrinology, 168(4), R77-83.

Leroy-Freschini, B., Amodru, V., Addeo, P., Sebag, F., Vix, M., Brunaud, L., Klein, M., Bahougne, T., ... Imperiale, A. (2019). Early (18)F-FDOPA PET/CT imaging after carbidopa premedication as a valuable diagnostic option in patients with insulinoma. European Journal of Nuclear Medicine and Molecular Imaging, 46(3), 686-695.

Luchini, C., Pantanowitz, L., Adsay, V., Asa, S. L., Antonini, P., Girolami, I., Veronese, N., Nottegar, A., ... Scarpa, A. (2022). Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring. Modern Pathology, 35(6), 712-720.

Margonis, G. A., Samaha, M., Kim, Y., Postlewait, L. M., Kunz, P., Maithel, S., Tran, T., Berger, N., ... Pawlik, T. M. (2016). A Multi-institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates Prognosis. Journal of Gastrointestinal Surgery, 20(6), 1098-105.

Massironi, S., Rossi, R. E., Zilli, A., Casazza, G., Ciafardini, C., & Conte, D. (2016). A wait-and-watch approach to small pancreatic neuroendocrine tumors: prognosis and survival. Oncotarget, 7(14), 18978-83.

Mazzaferro, V., Sposito, C., Coppa, J., Miceli, R., Bhoori, S., Bongini, M., Camerini, T., Milione, M., ... Mariani, L. (2016). The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. American Journal of Transplantation, 16(10), 2892-2902.

McCall, C. M., Shi, C., Cornish, T. C., Klimstra, D. S., Tang, L. H., Basturk, O., Mun, L. J., Ellison, T. A., ... Hruban, R. H. (2013). Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. American Journal of Surgical Pathology, 37(11), 1671-7.

McNamara, M. G., Swain, J., Craig, Z., Sharma, R., Faluyi, O., Wadsley, J., Morgan, C., Wall, L. R., ... Valle, J. W. (2023). NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma. EClinicalMedicine, 60, 102015.

Meng, M. B., Zaorsky, N. G., Jiang, C., Tian, L. J., Wang, H. H., Liu, C. L., Wang, J., Tao, Z., ... Ping, W. (2013). Radiotherapy and chemotherapy are associated with improved outcomes over surgery and chemotherapy in the management of limited-stage small cell esophageal carcinoma. Radiotherapy and Oncology, 106(3), 317-22.

Meulendijks, D., Henricks, L. M., Sonke, G. S., Deenen, M. J., Froehlich, T. K., Amstutz, U., Largiadèr, C. R., Jennings, B. A., ... Schellens, J. H. (2015). Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet. Oncology, 16(16), 1639-50.

Milione, M., Maisonneuve, P., Spada, F., Pellegrinelli, A., Spaggiari, P., Albarello, L., Pisa, E., Barberis, M., ... La Rosa, S. (2017). The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories. Neuroendocrinology, 104(1), 85-93.

Modlin, I. M., Lye, K. D., & Kidd, M. (2003). A 5-decade analysis of 13,715 carcinoid tumors. Cancer, 97(4), 934-59.

Modlin, I. M., Pavel, M., Kidd, M., & Gustafsson, B. I. (2010). Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Alimentary Pharmacology and Therapeutics, 31(2), 169-88.

Moertel, C. G., Hanley, J. A., & Johnson, L. A. (1980). Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine, 303(21), 1189-94.

Mollazadegan, K., Botling, J., Skogseid, B., Eriksson, B., Falkman, L., Zhang, L., Lase, I., Welin, S., ... Crona, J. (2025). The impact of re-characterizing metastatic pancreatic neuroendocrine tumors: A prospective study. Journal of Neuroendocrinology, 37(8), e70040.

Mulders, M. C. F., de Herder, W. W., & Hofland, J. (2024). What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed Mediators. Endocrine Reviews, 45(3), 351-360.

Nagtegaal, I. D., Odze, R. D., Klimstra, D., Paradis, V., Rugge, M., Schirmacher, P., Washington, K. M., Carneiro, F., & Cree, I. A. (2020). The 2019 WHO classification of tumours of the digestive system. Histopathology, 76(2), 182-188.

Nasjonal strategi for kreftområdet 2006-2009 (2006). Oslo: Helse- og omsorgsdepartementet. Hentet fra https://www.regjeringen.no/globalassets/upload/hod/sykehus/kreftstrategi-2006-2009.pdf

Nasjonal helseplan (2007-2010) (2006). (Særtrykk av St.prp. nr. 1 (2006–2007) kapittel 6.). Oslo: Helse- og omsorgsdepartementet. Hentet fra https://www.regjeringen.no/globalassets/upload/HOD/Sykehus/Nasjonal_helseplan_Sartrykk.pdf

Nesti, C., Bräutigam, K., Benavent, M., Bernal, L., Boharoon, H., Botling, J., Bouroumeau, A., Brcic, I., ... Kaderli, R. M. (2023). Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study. Lancet. Oncology, 24(2), 187-194.

Norlén, O., Stalberg, P., Oberg, K., Eriksson, J., Hedberg, J., Hessman, O., Janson, E. T., Hellman, P., & Akerstrom, G. (2012). Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World Journal of Surgery, 36(6), 1419-31.

Norton, J. A. (2005). Surgery and prognosis of duodenal gastrinoma as a duodenal neuroendocrine tumor. Best practice & research. Clinical gastroenterology, 19(5), 699-704.

Panzuto, F., Ramage, J., Pritchard, D. M., van Velthuysen, M. F., Schrader, J., Begum, N., Sundin, A., Falconi, M., & O'Toole, D. (2023). European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3. Journal of Neuroendocrinology, 35(8), e13306.

Pape, U. F., Perren, A., Niederle, B., Gross, D., Gress, T., Costa, F., Arnold, R., Denecke, T., ... Barcelona Consensus Conference, p. (2012). ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology, 95(2), 135-56.

Partelli, S., Landoni, L., Bartolomei, M., Zerbi, A., Grana, C. M., Boggi, U., Butturini, G., Casadei, R., ... Falconi, M. (2024). Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study. The British journal of surgery, 111(9)

Pavel, M., Baudin, E., Couvelard, A., Krenning, E., Oberg, K., Steinmuller, T., Anlauf, M., Wiedenmann, B., ... Barcelona Consensus Conference, p. (2012). ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology, 95(2), 157-76.

Pavel, M., Öberg, K., Falconi, M., Krenning, E. P., Sundin, A., Perren, A., & Berruti, A. (2020). Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 31(7), 844-860.

Pellikka, P. A., Tajik, A. J., Khandheria, B. K., Seward, J. B., Callahan, J. A., Pitot, H. C., & Kvols, L. K. (1993). Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation, 87(4), 1188-96.

Ramage, J. K., De Herder, W. W., Delle Fave, G., Ferolla, P., Ferone, D., Ito, T., Ruszniewski, P., Sundin, A., ... Vienna Consensus Conference, p. (2016). ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. Neuroendocrinology, 103(2), 139-43.

Raymond, E., Dahan, L., Raoul, J. L., Bang, Y. J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., ... Ruszniewski, P. (2011). Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine, 364(6), 501-13.

Regenet, N., Carrere, N., Boulanger, G., de Calan, L., Humeau, M., Arnault, V., Kraimps, J. L., Mathonnet, M., ... Mirallie, E. (2016). Is the 2-cm size cutoff relevant for small nonfunctioning pancreatic neuroendocrine tumors: A French multicenter study. Surgery, 159(3), 901-7.

Reid, M. D., Bagci, P., Ohike, N., Saka, B., Erbarut Seven, I., Dursun, N., Balci, S., Gucer, H., ... Adsay, V. (2015). Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Modern Pathology, 28(5), 686-94.

Rindi, G., Kloppel, G., Alhman, H., Caplin, M., Couvelard, A., de Herder, W. W., Erikssson, B., Falchetti, A., ... Wiedenmann, B. (2006). TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv, 449(4), 395-401.

Rinke, A., Muller, H. H., Schade-Brittinger, C., Klose, K. J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., ... Group, P. S. (2009). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology, 27(28), 4656-63.

Rinzivillo, M., Capurso, G., Campana, D., Fazio, N., Panzuto, F., Spada, F., Cicchese, N., Partelli, S., ... Delle Fave, G. (2016). Risk and Protective Factors for Small Intestine Neuroendocrine Tumours: A Prospectivecase-Control Study. Neuroendocrinology, 103(5), 531-7.

Sadot, E., Reidy-Lagunes, D. L., Tang, L. H., Do, R. K., Gonen, M., D'Angelica, M. I., DeMatteo, R. P., Kingham, T. P., ... Allen, P. J. (2016). Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study. Annals of Surgical Oncology, 23(4), 1361-70.

Sandvik, O. M., Soreide, K., Gudlaugsson, E., Kvaloy, J. T., & Soreide, J. A. (2016). Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria. British Journal of Surgery, 103(3), 226-32.

Sharma, A., Muralitharan, M., Ramage, J., Clement, D., Menon, K., Srinivasan, P., Elmasry, M., Reed, N., ... Srirajaskanthan, R. (2024). Current Management of Neuroendocrine Tumour Liver Metastases. Current Oncology Reports, 26(9), 1070-1084.

Sidrak, M. M. A., De Feo, M. S., Corica, F., Gorica, J., Conte, M., Filippi, L., Evangelista, L., De Vincentis, G., & Frantellizzi, V. (2023). Role of Exendin-4 Functional Imaging in Diagnosis of Insulinoma: A Systematic Review. Life (Basel, Switzerland), 13(4)

Singh, S., Halperin, D., Myrehaug, S., Herrmann, K., Pavel, M., Kunz, P. L., Chasen, B., Tafuto, S., ... Ferone, D. (2024). [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet, 403(10446), 2807-2817.

Sorbye, H., Baudin, E., & Perren, A. (2018). The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond. Endocrinology and Metabolism Clinics of North America, 47(3), 683-698.

Sorbye, H., Grande, E., Pavel, M., Tesselaar, M., Fazio, N., Reed, N. S., Knigge, U., Christ, E., ... Tiensuu Janson, E. (2023). European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. Journal of Neuroendocrinology, 35(3), e13249.

Sorbye, H., Hjortland, G. O., Vestermark, L. W., Ladekarl, M., Svensson, J., Sundlöv, A., Janson, E. T., Garresori, H., ... Langer, S. W. (2025). Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study. British Journal of Cancer, 133(3), 316-324.

Sorbye, H., Kong, G., Grozinsky-Glasberg, S., & Strosberg, J. (2025). PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). Journal of Neuroendocrinology, 37(3), e13443.

Sorbye, H., Meyer, L. S., Mordal, K. E., Myhre, S., & Thiis-Evensen, E. (2020). Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours. Health and quality of life outcomes, 18(1), 188.

Sorbye, H., Strosberg, J., Baudin, E., Klimstra, D. S., & Yao, J. C. (2014). Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer, 120(18), 2814-23.

Sorbye, H., Welin, S., Langer, S. W., Vestermark, L. W., Holt, N., Osterlund, P., Dueland, S., Hofsli, E., ... Knigge, U. (2013). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Annals of Oncology, 24(1), 152-60.

Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., ... Investigators, N. T. (2017). Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. New England Journal of Medicine, 376(2), 125-135.

Strosberg, J. R., Coppola, D., Klimstra, D. S., Phan, A. T., Kulke, M. H., Wiseman, G. A., Kvols, L. K., & North American Neuroendocrine Tumor, S. (2010). The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas, 39(6), 799-800.

Strosberg, J. R., Fine, R. L., Choi, J., Nasir, A., Coppola, D., Chen, D. T., Helm, J., & Kvols, L. (2011). First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 117(2), 268-75.

Strosberg, J. R., Koumarianou, A., Riechelmann, R., Hernando, J., Cingarlini, S., Crona, J., Al-Toubah, T. E., Apostolidis, L., ... De Mestier Du Bourg, L. (2025). Efficacy of immune checkpoint inhibitors in patients with advanced pancreatic NETs displaying high TMB and MMR alterations following treatment with alkylating agents. Journal of Clinical Oncology. Conference, 43(Supplement 4)

Søreide, K., Stättner, S., & Hallet, J. (2024). Surgery as a Principle and Technical Consideration for Primary Tumor Resection of Small Bowel Neuroendocrine Tumors. Annals of Surgical Oncology, 31(2), 1125-1137.

Thiis-Evensen, E., & Boyar Cetinkaya, R. (2023). Incidence and prevalence of neuroendocrine neoplasms in Norway 1993-2021. Journal of Neuroendocrinology, 35(4), e13264.

Toumpanakis, C. G., & Caplin, M. E. (2008). Molecular genetics of gastroenteropancreatic neuroendocrine tumors. American Journal of Gastroenterology, 103(3), 729-32.

Tropea, F., Baldari, S., Restifo, G., Fiorillo, M. T., Surace, P., & Herberg, A. (2006). Evaluation of chromogranin A expression in patients with non-neuroendocrine tumours. Clinical Drug Investigation, 26(12), 715-22.

Venizelos, A., Elvebakken, H., Perren, A., Nikolaienko, O., Deng, W., Lothe, I. M. B., Couvelard, A., Hjortland, G. O., ... Knappskog, S. (2021). The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocrine-Related Cancer, 29(1), 1-14.

Vijayvergia, N., Dasari, A., Deng, M., Litwin, S., Al-Toubah, T., Alpaugh, R. K., Dotan, E., Hall, M. J., ... Strosberg, J. R. (2020). Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials. British Journal of Cancer, 122(9), 1309-1314.

Waddell, N., Pajic, M., Patch, A. M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., ... Grimmond, S. M. (2015). Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518(7540), 495-501.

Welin, S., Sorbye, H., Sebjornsen, S., Knappskog, S., Busch, C., & Oberg, K. (2011). Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer, 117(20), 4617-22.

WHO Classification of Tumours Editorial Board (2019). Digestive System Tumours. IARC.

Xu, A., Suz, P., Reljic, T., Are, A. C., Kumar, A., Powers, B., Strosberg, J., Denbo, J. W., ... Anaya, D. A. (2022). Perioperative Carcinoid Crisis: A Systematic Review and Meta-Analysis. Cancers, 14(12), 2966.

Yachida, S., Vakiani, E., White, C. M., Zhong, Y., Saunders, T., Morgan, R., de Wilde, R. F., Maitra, A., ... Iacobuzio-Donahue, C. A. (2012). Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. American Journal of Surgical Pathology, 36(2), 173-84.

Yao, H., Sokas, C., & Welch, H. G. (2022). Rising Incidence of Cancer of the Small Intestine: Overdiagnosis and Better Diagnosis of Low-lethality Disease. Gastroenterology, 162(6), 1749-1751.e2.

Yao, J. C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E., Tomasek, J., Raderer, M., ... Rad001 in Advanced Neuroendocrine Tumours, F. T. S. G. (2016). Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet, 387(10022), 968-77.

Yao, J. C., Hassan, M., Phan, A., Dagohoy, C., Leary, C., Mares, J. E., Abdalla, E. K., Fleming, J. B., ... Evans, D. B. (2008). One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology, 26(18), 3063-72.

Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., ... Rad001 in Advanced Neuroendocrine Tumors, T. T. S. G. (2011). Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine, 364(6), 514-23.